SaiLong(SZ:002898) Shang Hai Zheng Quan Bao·2026-02-13 17:30Group 1 - The company plans to publicly transfer 100% equity of its wholly-owned subsidiary, Hunan Sailong Biopharmaceutical Co., Ltd., to optimize resource allocation and improve operational efficiency [2][4] - The initial public offering price for the equity was set at RMB 86.95 million, based on an assessment by Beijing Kunyuan Zhicheng Asset Appraisal Co., Ltd. [3][9] - The first public offering period ended without attracting any qualified buyers, leading the company to reduce the offering price by 10% to RMB 78.255 million for the next round of bidding [4][3] Group 2 - The subsidiary, Hunan Sailong Biopharmaceutical Co., Ltd., was established on July 19, 2017, with a registered capital of RMB 104.54 million and operates in drug production and sales [8] - The financial assessment indicated that the market value of the subsidiary's total equity was RMB 86.9439 million as of September 30, 2025 [9][10] - The company has completed a capital increase for the subsidiary, raising its registered capital from RMB 55 million to RMB 104.54 million as of January 14, 2026 [13] Group 3 - The board of directors approved the proposal for the public transfer of the subsidiary's equity, which will be submitted for shareholder approval [4][43] - The company aims to use the proceeds from the equity transfer to support its operational development, aligning with its strategic growth plans [15] - The company retains the right to terminate the transfer process if no qualified buyers are found after subsequent rounds of bidding [4][5]